Biodesix Inc (BDSX)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics...

Form 8-K - Current report

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biodesix Announces First Quarter 2026 Results and Highlights

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026;...

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Biodesix Recognized as a Top Workplace for Third Consecutive Year

LOUISVILLE, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Biodesix is proud to announce that it has earned the...